Ziltivekimab antagonism of IL-6 reduces inflammation and thrombosis in patients with atherosclerotic risk factors

1. Ziltivekimab lowered high-sensitivity CRP levels, a predictor of vascular events, compared to placebo in a dose-dependent manner. 2. Thrombotic biomarkers including fibrinogen, serum amyloid...

Voclosporin shows clinical promise for treatment of active lupus nephritis

1. A significantly greater proportion of patients in the voclosporin group achieved complete renal responses after 52 weeks compared to the placebo group. 2. The...

Reduced-dose glucocorticoid adjunct non-inferior to high-dose glucocorticoid plus rituximab regimen for induction of disease...

1. Reduced-dose glucocorticoid plus rituximab regimen was non-inferior compared to high-dose glucocorticoid plus rituximab regimen for induction of disease remission in ANCA-associated vasculitis  Evidence Rating...

Cardiovascular safety of hydroxychloroquine in veterans with rheumatoid arthritis

1. Among a large, matched cohort of veterans with rheumatoid arthritis, initiation of hydroxychloroquine was not associated with a higher risk of adverse cardiovascular...

Upadacitinib non-inferior to adalimumab for psoriatic arthritis treatment

1. Janus kinase (JAK) inhibitor upadacitinib showed non-inferior efficacy in improving psoriatic arthritis compared to standard-of-care adalimumab. 2. High-dose upadacitinib was associated with more frequent...

Bimekizumab superior to secukinumab for plaque psoriasis treatment

1. Bimekizumab treatment was shown to be noninferior and superior for greater skin clearance of plaque psoriasis compared to secukinumab treatment. 2. Bimekizumab treatment was...

All-time hits